Whitehawk Therapeutics
WHWK
24 hedge funds and large institutions have $18.3M invested in Whitehawk Therapeutics in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
20% more funds holding
Funds holding: 20 → 24 (+4)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.49% less ownership
Funds ownership: 28.06% → 26.57% (-1.5%)
64% less capital inflows, than outflows
Capital inflows: $1.1M | Capital outflows: $3.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$514K |
| 2 |
Harbourvest Partners
Boston,
Massachusetts
|
+$307K |
| 3 |
Jane Street
New York
|
+$119K |
| 4 |
Bank of New York Mellon
New York
|
+$45.4K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$34.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.75M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$639K |
| 3 |
Goldman Sachs
New York
|
-$335K |
| 4 |
CVI Holdings
Wilmington,
Delaware
|
-$263K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$31K |
WHWK Hedge Fund Activity: Q4 2018 in Review
24 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2018, worth a combined $18.3M — down 48% from $35.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new WHWK positions and 4 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $514K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.75M sold.
- 24 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2018, up from 20 in Q3 2018.
- Funds reported $18.3M of Whitehawk Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
- 8 funds opened new Whitehawk Therapeutics positions in Q4 2018 and 4 closed out, a net change of +4 holders.
- The largest Whitehawk Therapeutics buyer in Q4 2018 was Citigroup, an estimated $514K added.
- The largest Whitehawk Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $1.75M sold.
Based on aggregated 13F filings for Q4 2018.